Scleroderma Insights

Cell and gene therapies are transforming rare disease treatment, offering new hope where options were once limited. But how do they work, and what choices exist for your community?

We're launching a special content series to help our 15k+ readers navigate this evolving landscape – and we need your voice!

In a systematic review by Nilforoushzadeh et al. (2025), platelet-rich plasma (PRP) therapy was examined for its effectiveness and safety in treating scleroderma. The review included 11 studies and found that PRP, which is rich in platelets and growth factors, improved skin elasticity, aided in healing skin ulcers, and enhanced vascularization in systemic sclerosis (SSc). It also reduced the severity of localized scleroderma (LoSc) symptoms, decreased pain, and even led to hair regrowth in patients with a specific form of LoSc known as en coupe de sabre.

These benefits were observed when PRP was used alone or in combination with other treatments like hyaluronic acid. The reported side effects were minor and temporary, suggesting that PRP is a safe adjunct therapy. Nilforoushzadeh et al. concluded that PRP could be a promising option to complement standard treatments for both SSc and LoSc.